Novo Nordisk to Invest €2.1 Billion in French Production Site
Novo Nordisk wants to make another major capital investment in production capacity for its diabetes and obesity therapies. The Danish drugmaker announced to spend more than 16 billion Danish kroner (€2.1 billion euros) starting in 2023 to expand its production site in Chartres, France, adding aseptic production and finished production processes and an extension of the current Quality Control Laboratory.
According to Novo Nordisk, the facility, which will more than double the site's footprint, will be designed as a multi-product facility to accommodate current and future processes.
“Our continued investments in our manufacturing sites across the globe demonstrate the belief we have in our current and future product portfolio and its relevance for people living with serious chronic diseases,” said Henrik Wulff, Novo Nordisk’s executive vice president, Product Supply, Quality & IT.
The construction projects, Novo Nordisk said, are already underway and will be completed in stages between 2026 and 2028. The investment is expected to create more than 500 new jobs.
Source: Novo Nordisk
